Nobuko Maruyama

718 total citations
14 papers, 618 citations indexed

About

Nobuko Maruyama is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Organic Chemistry. According to data from OpenAlex, Nobuko Maruyama has authored 14 papers receiving a total of 618 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Surgery, 13 papers in Endocrinology, Diabetes and Metabolism and 1 paper in Organic Chemistry. Recurrent topics in Nobuko Maruyama's work include Pancreatic function and diabetes (12 papers), Diabetes Treatment and Management (12 papers) and Diabetes Management and Research (10 papers). Nobuko Maruyama is often cited by papers focused on Pancreatic function and diabetes (12 papers), Diabetes Treatment and Management (12 papers) and Diabetes Management and Research (10 papers). Nobuko Maruyama collaborates with scholars based in Japan, United States and Netherlands. Nobuko Maruyama's co-authors include Nobuya Inagaki, Hiroaki Iijima, Kazuoki Kondo, Maki Goda, Toru Yoshinari, Yutaka Susuta, Yutaka Kawaguchi, Shin‐ichi Harashima, Kohei Kaku and Yumi Watanabe and has published in prestigious journals such as British Journal of Clinical Pharmacology, Diabetes Obesity and Metabolism and Cardiovascular Diabetology.

In The Last Decade

Nobuko Maruyama

14 papers receiving 605 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nobuko Maruyama Japan 12 566 321 254 77 67 14 618
Aliza Rozenberg Israel 13 663 1.2× 266 0.8× 206 0.8× 62 0.8× 64 1.0× 26 753
Ilan Yanuv Israel 13 663 1.2× 265 0.8× 206 0.8× 62 0.8× 64 1.0× 25 751
John Xu United States 14 406 0.7× 257 0.8× 171 0.7× 30 0.4× 95 1.4× 24 560
R. Qiu United States 3 463 0.8× 231 0.7× 171 0.7× 88 1.1× 25 0.4× 5 483
Elke Seewaldt-Becker Germany 7 972 1.7× 588 1.8× 510 2.0× 160 2.1× 67 1.0× 7 1.1k
Claire C. J. Dekkers Netherlands 9 599 1.1× 319 1.0× 210 0.8× 74 1.0× 132 2.0× 13 734
R. Roßkamp Germany 14 413 0.7× 193 0.6× 205 0.8× 23 0.3× 95 1.4× 32 654
Ludwig Merker Germany 10 1.3k 2.3× 719 2.2× 525 2.1× 193 2.5× 61 0.9× 30 1.4k
Josselin Nespoux United States 6 334 0.6× 220 0.7× 150 0.6× 30 0.4× 76 1.1× 14 491
Rishi Patel United States 5 452 0.8× 165 0.5× 182 0.7× 74 1.0× 27 0.4× 9 538

Countries citing papers authored by Nobuko Maruyama

Since Specialization
Citations

This map shows the geographic impact of Nobuko Maruyama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nobuko Maruyama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nobuko Maruyama more than expected).

Fields of papers citing papers by Nobuko Maruyama

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nobuko Maruyama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nobuko Maruyama. The network helps show where Nobuko Maruyama may publish in the future.

Co-authorship network of co-authors of Nobuko Maruyama

This figure shows the co-authorship network connecting the top 25 collaborators of Nobuko Maruyama. A scholar is included among the top collaborators of Nobuko Maruyama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nobuko Maruyama. Nobuko Maruyama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Harashima, Shin‐ichi, Nobuya Inagaki, Kazuoki Kondo, et al.. (2018). Efficacy and safety of canagliflozin as add‐on therapy to a glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week, open‐label, phase IV study. Diabetes Obesity and Metabolism. 20(7). 1770–1775. 22 indexed citations
2.
Polidori, David, Hiroaki Iijima, Maki Goda, et al.. (2018). Intra‐ and inter‐subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co‐transporter 2 inhibitor canagliflozin. Diabetes Obesity and Metabolism. 20(5). 1321–1326. 58 indexed citations
3.
4.
Inagaki, Nobuya, Shin‐ichi Harashima, Kohei Kaku, et al.. (2017). Long‐term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus. Diabetes Obesity and Metabolism. 20(4). 812–820. 11 indexed citations
5.
Kadowaki, Takashi, Nobuya Inagaki, Kazuoki Kondo, et al.. (2017). Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in J apanese patients with type 2 diabetes mellitus: R esults of a 24‐week, randomized, double‐blind, placebo‐controlled trial. Diabetes Obesity and Metabolism. 19(6). 874–882. 49 indexed citations
6.
Kadowaki, Takashi, Nobuya Inagaki, Kazuoki Kondo, et al.. (2017). Long‐term safety and efficacy of canagliflozin as add‐on therapy to teneligliptin in J apanese patients with type 2 diabetes. Diabetes Obesity and Metabolism. 20(1). 77–84. 13 indexed citations
7.
Inagaki, Nobuya, Shin‐ichi Harashima, Nobuko Maruyama, et al.. (2016). Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus. Cardiovascular Diabetology. 15(1). 89–89. 60 indexed citations
8.
Tanaka, Hiroyuki, Kazuhiko Takano, Hiroaki Iijima, et al.. (2016). Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus. Advances in Therapy. 34(2). 436–451. 113 indexed citations
9.
10.
11.
Iijima, Hiroaki, et al.. (2015). Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Advances in Therapy. 32(8). 768–782. 52 indexed citations
12.
Ford, J., D. E. Fowler, Nobuko Maruyama, et al.. (2014). Tolerability, pharmacokinetics and pharmacodynamics of TA‐8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. British Journal of Clinical Pharmacology. 78(3). 498–508. 43 indexed citations
13.
Inagaki, Nobuya, et al.. (2013). Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, 12‐week study. Diabetes Obesity and Metabolism. 15(12). 1136–1145. 120 indexed citations
14.
Aoki, Takashi, Kohei Sanui, Naoya Ogata, et al.. (1998). Surface and Interface-New Functions of Biorelated Polymers I. Interpolymer Complexes between Poly(N,N-dimethylacrylamide) and Poly(acrylic acid) in Aqueous System.. KOBUNSHI RONBUNSHU. 55(4). 225–229. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aliza Rozenberg Breakdown of academic impact, for papers by Ilan Yanuv Breakdown of academic impact, for papers by John Xu Breakdown of academic impact, for papers by R. Qiu Breakdown of academic impact, for papers by Elke Seewaldt-Becker Breakdown of academic impact, for papers by Claire C. J. Dekkers Breakdown of academic impact, for papers by R. Roßkamp Breakdown of academic impact, for papers by Ludwig Merker Breakdown of academic impact, for papers by Josselin Nespoux Breakdown of academic impact, for papers by Rishi Patel
Rankless by CCL
2026